Femasys Inc
NASDAQ:FEMY

Watchlist Manager
Femasys Inc Logo
Femasys Inc
NASDAQ:FEMY
Watchlist
Price: 1.24 USD 14.81% Market Closed
Market Cap: 33.7m USD

Femasys Inc
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Femasys Inc
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Femasys Inc
NASDAQ:FEMY
Tax Provision
-$9.6k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Tax Provision
-$233m
CAGR 3-Years
N/A
CAGR 5-Years
-38%
CAGR 10-Years
2%
Boston Scientific Corp
NYSE:BSX
Tax Provision
-$436m
CAGR 3-Years
-130%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Tax Provision
-$499m
CAGR 3-Years
-20%
CAGR 5-Years
-1%
CAGR 10-Years
3%
Abbott Laboratories
NYSE:ABT
Tax Provision
$6.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Tax Provision
-$336.3m
CAGR 3-Years
-28%
CAGR 5-Years
-23%
CAGR 10-Years
-10%

Femasys Inc
Glance View

Market Cap
33.7m USD
Industry
Health Care

Femasys, Inc. operates as a medical device company that focuses on women's healthcare. The company is headquartered in Suwanee, Georgia. The company went IPO on 2021-06-18. The firm is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The firm also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.

FEMY Intrinsic Value
2.26 USD
Undervaluation 45%
Intrinsic Value
Price

See Also

What is Femasys Inc's Tax Provision?
Tax Provision
-9.6k USD

Based on the financial report for Dec 31, 2024, Femasys Inc's Tax Provision amounts to -9.6k USD.

What is Femasys Inc's Tax Provision growth rate?
Tax Provision CAGR 1Y
-123%

Over the last year, the Tax Provision growth was -123%.

Back to Top